Influenza

Principles and Practice of Clinical Virology: Sixth Edition

Volumn , Issue , 2009, Pages 373-408

  Zambon, Maria ^a   Potter, Chris W ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Neuraminidase inhibitors; Otitis media; Reye's syndrome; Split virus vaccines; Sudden infant death syndrome (SIDS); Zoonotic infections

Indexed keywords

EID: 77954946337     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470741405.ch16     Document Type: Chapter

References (117)

1. Abramson, J.S., Neuzil, K.M. and Tamblyn, S.E. (2006) Annual universal influenza vaccination: ready or not? Clinical Infectious Diseases, 42, 132-35.
2. Arruda, E. and Hayden, F.G. (1996) Update on therapy of influenza and rhinovirus infections. Antiviral Chemistry and Chemotherapy, 4, 175-87.
3. Beare, A.A.A.S. (ed.) (1982) Research into immunisation of humans against influenza by means of living viruses, in Basic and APpield Influenza Resseach, CRC Press, Boca Raton, FL, pp. 211-34.
4. Beigel, J.H., Farrar, J., Han, A.M. et al. (2005) Writing committee of the World Health Organization (WHO) consultation on human influenza A/H5.Avian influenza A (H5N1) infection in humans. The New England Journal of Medicine, 353, 1374-85.
5. Belshe, R.B., Edwards, K.M., Vesikari, T. et al. (2007) CAIV-T comparative efficacy study group. Live attenuated versus inactivated influenza vaccine in infants and young children. The New England Journal of Medicine, 356, 1283-88.
6. Bhat, N., Wright, J.G., Broder, K.R.et al. (2005)Influenza special investigations team. Influenza-associated deaths among children in the United States, 2003-2004. The New England Journal of Medicine, 353, 2559-67.
7. Blok, V., Cianci, C., Tibbles, K.W. et al. (1996) Inhibition of the influenza virus RNA-dependent RNA polymerase by antisera directed against the carboxy-terminal region of the PB2 subunit. The Journal of General Virology, 77, 1025-33.
8. Bradbury, T.N. and Miller, G.A. (2000) Season of birth in schizophrenia: a review of evidence, methodology and aetiology. Psychological Bulletin, 98, 569-94.
9. Bresson, J.L., Perronne, C., Launay, O. et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet, 367 (9523), 1657-64.
10. Bright, R.A., Medina, M.J., Xu, X. et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet, 366 (9492), 1175-81.
11. Chen, W., Calvo, P.A., Malide, D. et al. (2001) A novel influenza a mitochondrial protein that induces cell death. Nature Medicine, 7, 1306-12.
12. Colman, P. (1998) Structure and function of neuraminidase, in Textbook of Influenza (eds K.G. Nicholson, R.G. Webster and A.J. Hay), Blackwell, London, pp. 65-73.
13. Conover, R.T. and Rossmann, U. (1990) Malformation complex in an infant with intrauterine influenza viral infection. Archives of Pathology and Laboratory Medicine, 114, 535.
14. Crosby, A.W. (1976) Epidemic and Peace, 1918 , Greenwood Press, Westford CT. de Jong, J.C., Claas, E.C.J. and Osterhaus, A.D.M.E. (1997) A pandemic warning. Nature, 389, 534.
15. de Jong, M.D. and Hien, T.T. (2006) Avian influenza a (H5N1). Journal of Clinical Virology, 35, 2-13.
16. de Jong, M., Thanh, T.T., Khank, T.H. et al. (2005) Oseltimivir resistance during treatment of influenza H5N1. The New England Journal of Medicine, 353, 25-30.
17. Drape, R.J., Macklin, M.D., Barr, L.J. et al. (2006) Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine, 24 (21), 4475-81.
18. Ellis, J.S. and Zambon, M.C. (2002) Molecular diagnosis of influenza. Reviews in Medical Virology, 12, 375-89.
19. Elton, D., Medcalf, L. and Bishop, K. (1999) Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. Journal of Virology, 73, 7357-67.
20. Fleming, D.M. (2000) The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Communicable Disease and Public Health, 3, 32-38.
21. Fodor, E., Devenish, L., Engelhardt, O.G. et al. (1999) Rescue of influenza A virus from recombinant DNA. Journal of Virology, 73 (11), 9679-82.
22. Francis, T. Jr, Davenport, F.M. and Hennessy, A.V. (1953) A serological recapitulation of human infection with different strains of influenza virus. Transactions of the Association of American Physicians, 66, 231-39.
23. Gambotto, A., Barratt-Boyes, S.M., de Jong, M.D. et al. (2008) Human infection with highly pathogenic H5N1 influenza virus. Lancet, 371, 1464-75.
24. García-Sastre, A. (2001) Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology, 279, 375-84.
25. Gentile, D., Doyle, W., Whiteside, T. et al. (1998) Increased interleukin-6 levels in ansal lavage samples following experimental influenza A virus infection. Clinical and Diagnostic Laboratory Immunology, 5, 604-8.
26. Ǵomez-Puertas, P., Albo, C., Ṕerez-Pastrana, E. et al. (2000) Influenza virus matrix protein is the major driving force in virus budding. Journal of Virology, 75, 11538-47.
27. Gregory, V., Bennett, M., Orkhan, M.H. et al. (2002) Emergence of influenza A H1N2 reassortant viruses in the human population during 2001. Virology, 300, 1-7.
28. Ha, Y., Stevens, D.J., Skehel, J.J. and Wiley, D.C. (2002). H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. The EMBO Journal, 21 (5), 865-75.
29. Hayden, F.G. (1996) Combination antiviral therapy for respiratory virus infections. Antiviral Research, 29, 45-48.
30. Hayden, F.G., Fritz, R., Lobo, M.C. et al. (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. The Journal of Clinical Investigation, 101 (3), 643-49.
31. Hayden, F.G. and Pavia, A.T. (2006) Antiviral management of seasonal and pandemic influenza. The Journal of Infectious Diseases, 194 (Suppl 2), S119-S126.
32. Holmes, E.C., Ghedin, E., Miller, N. et al. (2005). Whole genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. Public Libary of Science 3 (9), e300.
33. Hope Simpson, E. (1981) The role of season in the epidemiology of influenza. The Journal of Hygiene, 86, 35-47.
34. Irvine, W.K., James, D.K., Stephenson, T. et al. (2000) Influenza virus infection in the second and third trimester of pregnancy; a clinical and socioepidemiological study. British Journal of Obstetrics and Gynaecology, 107, 1289-90.
35. Keitel, W.A., Cate, T.R., Atmar, R.L. et al. (1996) Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clinical and Diagnostic Laboratory Immunology, 3, 507-10.
36. Kitler, M.E., Gavinio, P. and Lavanchy, D. (2000) Influenza and the work of the World Health Organization. Vaccine, 20 (S2), 5-14.
37. Kobasa, D., Jones, S.M., Shinya, K. et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature, 445, 319-23.
38. Koopmans, M., Wilbrink, B., Conyn, M. et al. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. The Lancet, 363 (9409), 587-93.
39. Lackenby, A., Hugnes, O., Dudman, S.G. et al. (2008). Emergence of resistance to oseltamivir amongst influenza A(H1n1) viruses in Europe(2008). Eurosurveillance, 13 (5), 8026.
40. Lamb, R.A. and Krug, R.M. (1996) Orthomyxoviridae: the viruses and their replication. in Field's Virology, 3rd edn (eds B.N. Fields, D.M. Knipe and P.M. Howley), Lippincott-Raven, Philadelphia, PA, pp. 1353-95.
41. Laver, W.G., Bischofberger, N. and Webster, R.G. (1999) Disarming flu viruses. Scientific American, 280, 78-87.
42. Laver, W.G., Colman, P.M., Ward, C.W. et al. (1984) Influenza virus neuraminidase: structure and variation, in The Molecular Biology and Epidemiology of Influenza (eds C.H. Stuart-Harris and C.W. Potter), Academic Press, London, pp. 77-89.
43. Leroux-Roels, I., Borkowski, A., Vanwolleghem, T. et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet, 370 (9587), 580-89.
44. Lin, T.-I., Heider, J. and Schroeder, C. (1997) Different modes of inhibition by amantane amine derivatives and natural polyamines of the functionally reconstituted influenza M2 proton channel protein. The Journal of General Virology, 78, 767-74.
45. Liu, J., Lynch, P.A., Chien, C.-Y. et al. (1997) Crystal structure of the unique structural multifunctional RNA-binding domain of the influenza virus NS1 protein. Nature Structural Biology, 4, 891-99.
46. Lynberg, M.C., IKhovry, M.J., Lu, X., et al. (1994) Maternal 'flu, and the risk of neural tube defects: a population-based case control study. American Journal of Epidemiology, 140, 244-55.
47. Maassab, H.F. and DeBorde, D.C. (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine, 3, 355-69.
48. Matrosovich, M.N., Gambaryan, A.S., Teneberg, S. et al. (1997) Avian influenza viruses differ from human viruses by recognition of sialoligo-saccharides and gangliosides and by a higher concentration of the HA receptor-binding site. Virology, 223, 224-34.
49. Matrosovich, M. and Klenk, H.-D. (2002) Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Reviews in Medical Virology, 12, 1-13.
50. Matrosovich, M., Matrosovich, T., Carr, J. et al. (2003) Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. Journal of Virology, 77, 8418-25.
51. McGeer, A., Green, K.A., Plevneshi, A. et al. (2007) Toronto invasive bacterial diseases network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clinical Infectious Diseases, 45 (12), 1568-75.
52. McKimm-Breschkin, J.L., Selleck, P.W., Usman, T.B. and Johnson, M.A. (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases, 13 (9), 1354-57.
53. McKimm-Breschkin, J., Trivedi, T., Hampson, A. et al. (2003). Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrobial Agents and Chemotherapy, 47 (7), 2264-72.
54. McMichael, A.J., Gotch, F.M., Noble, G.R. et al. (1983) Cytotoxic T-cell immunity to influenza. The New England Journal of Medicine, 309, 13-17.
55. Monto, A.S., Fleming, D.M., Henry, D. et al. (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. The Journal of Infectious Diseases, 180, 254-61.
56. Monto, A.S., McKimm-Breschkin, J.L., Macken, C. et al. (2006). Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrobial Agents and Chemotherapy, 50 (7), 2395-402.
57. Mori, I., Nagafuji, H., Matsumoto, K. et al. (1997) Use of the polymerase chain reaction for demonstrations of influenza virus dissemination in children. Clinical Infectious Diseases, 24, 736-37.
58. Morishima, T., Togashi, T., Yokota, S. et al. (2002) Collaborative Study Group on Influenza-Associated Encephalopathy in Japan. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clinical Infectious Diseases, 35, 512-17.
59. Murphy, B.R. and Clements, M.L. (1989) The systemic and mucosal immune response of humans to influenza A virus. Review. Current Topics in Microbiology and Immunology, 146, 107-16.
60. Mutsch, M., Zhou, W., Rhodes, P., Bopp, M. et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. The New England Journal of Medicine, 350, 896-903.
61. Neumann, G., Watanabe, T., Ito, H. et al. (1999). Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences of the United States of America, 96, 9345-50
62. Neuzil, K.M. (2004) Influenza vaccine for children. Clinical Infectious Diseases, 38 (5), 689-91.
63. Nichol, K.L. and Treanor, J.J. (2006) Vaccines for seasonal and pandemic influenza. The Journal of Infectious Diseases, 194 (Suppl 2), S111-S118.
64. Nicholson, K.G. (1998). Textbook of Influenza, (eds R.G. Webster, A.J. Hay and K. Nicholson), Blackwell. Nicholson, K.G., Aoki, F.Y. and Osterhaus, A.D.M.E. (2000) Efficacy and safety of oseltamivir in treatment ofacute influenza: a randomised controlled trial. Lancet, 355, 1845-50.
65. Nicholson, K.G., Colegate, A.E., Podda, A. et al. (2001) Confronting a potential H5N1 pandemic: a randomised controlled trial of conventional and MF59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) surface antigen vaccine. Lancet, 357, 1937-43.
66. Nicholson, K.G., Wood, J.M. and Zambon, M. (2003) Influenza. Lancet, 362, 1733-45.
67. NISN WER 2007 Monitoring of Neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Global surveillance (Weekly Epidemiol Report 27th April 2007)
68. Obenauer, J.C., Denson, J., Mehta, P.K. et al. (2006) Large-scale sequence analysis of avian influenza isolates. Science, 311, 1576-80.
69. O'Callaghan, E. (1991) Schizophrenia after post-natal exposure to 1957 H2-influenza epidemic. Lancet, 337, 1248-50.
70. O'Hagan, D.T., Wack, A. and Podda, A. (2007) MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clinical Pharmacology and Therapeutics, 82 (6), 740-44.
71. Ohmit, S.E., Victor, J.C., Rotthoff, J.R. et al. (2006) Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. The New England Journal of Medicine, 355, 2513-22.
72. Ortiz, J.R., Katz, M.A., Mahmoud, M.N. et al. (2007) Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. The Journal of Infectious Diseases, 196, 1685-91.
73. Palese, P. (2005) Modulation of Host Gene Expression and Innate Immunity by Viruses (eds J.P. Changeux and P. Palese), Springer.
74. Paragas, J., Talon, J., O'Neill, R.E. et al. (2001) Influenza B and C virus NEP (NS2) proteins possess nuclear export activities. Journal of Virology, 75, 7375-83.
75. Portela, A., Zucher, T., Nieto, A. et al. (1999) Replication of orthomyxoviruses. Advances in Virus Research, 54, 319-48.
76. Potter, C.W. (1998) Chronicle of influenza pandemics, in Textbook of Influenza (eds K.G. Nicholson, R.G. Webster and A.J. Hay), Blackwell, London, pp. 291-313.
77. Potter, C.W. (2001) A history of influenza. Journal of Applied Microbiology, 91, 1-8.
78. Potter, C.W. and Oxford, J.S. (1977) Animal models of influenza virus infection as applied to the investigation of antiviral compounds, in Chemoprophylaxis and Virus Infections of the Respiratory Tract, Vol. 2 (ed J.S. Oxford), CRC Press, Boca Raton, FL, pp. 1-26.
79. Potter, C.W. and Oxford, J.S. (1979) Determinants of immunity to influenza infections in man. British Medical Bulletin, 35, 69-75.
80. Reye, R.D.K., Morgan, C. and Baral, J. (1963) Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood. Lancet, 2, 749-52.
81. Rogers, G.N., Herrler, G., Paulson, J.C. and Klenk, H.D. (1986) Influenza C uses 9-O acetyl- N acetylneuraminic acid as a high affinity receptor for attachment to cells. The Journal of Biological Chemistry, 261, 5947-51.
82. Rogers, G.N., Pritchett, T.J., Lane, J.L. and Paulson, J.C. (1983) Differential sensitivity of human, avian, and equine influenza A viruses to a glycoprotein inhibitor of infection: selection of receptor specific variants. Virology, 13, 394-408.
83. Russell, R.J., Haire, L.F., Stevens, D.J. et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Natura, 443, 45-49.
84. Russell, C.A., Jones, T.C., Barr, I.G. et al. (2008) The global circulation of seasonal influenza A(H3N2) viruses. Science, 320, 340-45.
85. Schunemann, H., Hill, S.R., Kakad, M. et al. (2007) WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1). The Lancet Infectious Diseases, 7, 21-31.
86. Simonsen, L., Clark, M.J., Schonberg, L.B. et al. (1998) Pandemic versus epidemic influenza morality: a pattern of changing age distribution. The Journal of Infectious Diseases, 178, 53-60.
87. Shinya, K., Ebina, M., Yamada, S. et al. (2006) Avian flu: influenza virus receptors in the human airway. Nature, 440, 435-36.
88. Shinya, K., Hatta, M., Yamada, S. et al. (2005) Characterization of a human H5N1 influenza A virus isolated in 2003. Journal of Virology, 79, 9926-32.
89. Sidwell, R.W. and Smee, D.F. (2002) Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Review. Expert Opinion on Investigational Drugs, 11, 859-69.
90. Skehel, J.J., Daniels, R.S., Douglas, A.R. et al. (1984) Studies on the Haemagglutinin, in The Molecular Biology and Epidemiology of Influenza (eds C.H. Stuart-Harris and C.W. Potter), Academic Press, London, pp. 61-68.
91. Smith, D.J., Lapedes, A.S., de Jong, J.C. et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science, 305, 371-76.
92. Stein, D.S., Creticos, C.M., Jackson, G.G. et al. (1987) Oral ribavirin treatment of influenza A and B. Antimicrobial Agents and Chemotherapy, 31, 1285-87.
93. Steinhauer, D.A. (1999) Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology, 258 (1), 1-20.
94. Stephenson, I., Nicholson, K.G., Colegate, A. et al. (2003a) Boosting immunity to influenza H5N3 with MF59 adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine, 21 (15), 1687-93.
95. Stephenson, I., Wood, J.M., Nicholson, K.G. and Zambon, M.C. (2003b) Change in receptor specificity of erythrocytes affects haemagglutination-inhibition detection of antibodies to avian influenza haemagglutinin. Journal of Medical Virology, 70, 391-98.
96. Stephenson, I., Nicholson, K.G., Wood, J.M. et al. (2004) Confronting the avian influenza threat: vaccine development for a potential pandemic. The Lancet Infectious Diseases, 4, 499-509.
97. Stray, S.J., Cummings, R.D. and Air, G.M. (2000) Influenza virus infections of desialylated cells. Glycobiology, 10, 649-58.
98. Stuart-Harris, C.H., Schild, G.C. and Oxford, J.S. (1985) Influenza: The Viruses and the Disease, Edward Arnold, London, pp. 22-40.
99. Suzuki, Y., Ito, T., Suzuki, T. et al. (2001) Sialyl sugar chains as receptors and determinants of host range of influenza A viruses, in Options for the Control of Influenza, Vol. 4 (eds A. Osterhaus, N. Cox and A. Hampson), Excerpta Medica, Amsterdam, pp. 521-25.
100. Tashiro, M., Ciborowski, O., Klenk, H-D. et al. (1987) Role of staphylococcus aureus in the development of influenza pneumonia. Nature 325, 536-37.
101. Taubenberger, J.K., Reid, A.H., Krfaft, A.E. et al. (1997) Initial genetic characterisation of the 1918 'Spanish Influenza virus'. Science, 275, 1793-96.
102. Thompson, C.I., Barclay, W.S., Zambon, M.C. and Pickles, R.J. (2006) Infection of human airway epithelium by human and avian strains of influenza a virus. Journal of Virology, 80, 8060-68.
103. To, K.F., Chan, P.K.S., Chan, K.-F. et al. (2001) Pathology of fatal human infection associated with avian influenza A H5N1 virus. Journal of Medical Virology, 63, 242-46.
104. Treanor, J.J., Campbell, J.D., Zangwill, K.M. et al. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. The New England Journal of Medicine, 354 (13), 1343-51.
105. Treanor, J.J., Schiff, G.M., Hayden, F.G. et al. (2007) Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 29, 1577-82.
106. van Riel, D., Munster, V.J., de Wit, E. et al. (2007) Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. American Journal of Pathology, 171, 1215-23.
107. Vu, T., Farish, S., Jenkins, M. and Kelly, H. (2002) A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine; 20 (13-14), 1831-36.
108. Wang, P., Palese, P. and O'Neill, R.E. (1997) The NP1-1/NP1-3 (karyopherin) binding site of the influenza A virus nucleoprotein NP is a nonconventional nuclear location signal. Journal of Virology, 83, 337-55.
109. Webby, R.J., Rossow, K., Erickson, G. et al. (2004) Multiple lineages of antigenically and genetically diverse influenza A virus co-circulate in the United States swine population. Virus Research, 103, 67-73.
110. Webby, R.J., Webster, R.G. and Richt, J.A. (2007) Influenza viruses in animal wildlife populations. Review. Current Topics in Microbiology and Immunology, 315, 67-83.
111. Weinberg, G.A., Erdman, D.D., Edwards, K.M. et al. New Vaccine Surveillance Network Study Group (2004) Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. The Journal of Infectious Diseases, 189, 706-10.
112. Wood, J. M. (1991) Vaccines and Immunotherapy (ed S.J. Cruz), Pergamon Press.
113. Wong, J.P., Zabielski, M.A., Schmaltz, F.L. et al. (2001) DNA vaccination against respiratory influenza virus infection. Vaccine, 19, 2461-67.
114. WHO http://www.who.int/csr/disease/avian influenza /ai timeline/en/index.html.
115. Zambon, M. (1998) Laboratory diagnosis of influenza, in Textbook of Influenza (eds K.G. Nicholson, R.G. Webster and A.J. Hay), Blackwell, London, pp. 291-313.
116. Zambon, M.C., Hays, J., Webster, A. et al. (2001) Diagnosis of Influenza in the community: relationship of clinical diagnosis to confirmed virological, serological or molecular diagnosis. Archives of Internal Medicine, 161, 2116-22.
117. Zink, P., Drescher, J., Verhagen, W. et al. (1987) Serological evidence of recent influenza A (H3N2) infections in forensic cases of sudden infant death syndrome (SIDS). Archives of Virology, 93, 223-32.